Warning: session_start(): Cannot send session cookie - headers already sent by (output started at /home2/don/public_html/daily-enews-archives.php:5) in /home2/don/public_html/header08.php on line 1

Warning: session_start(): Cannot send session cache limiter - headers already sent (output started at /home2/don/public_html/daily-enews-archives.php:5) in /home2/don/public_html/header08.php on line 1
OBR Daily - Our Oncology Focused E-News Service

Register for OBR daily



Warning: Missing argument 1 for showSidebarBanner(), called in /home2/don/public_html/sidebar_obrgreen.php on line 38 and defined in /home2/don/public_html/include/banners.php on line 243
FM_ROS_300x250

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

IDRA $2.80 0.2100 +8.11%
NKTR $15.93 0.9500 +6.34%
CRIS $1.43 0.0700 +5.15%
BCRX $11.16 0.5400 +5.08%
ARQL $1.29 0.0600 +4.88%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

PARD $0.15 -0.0500 -25.00%
GERN $3.59 -0.2500 -6.51%
FATE $3.76 -0.2300 -5.76%
ARWR $5.84 -0.3250 -5.27%
THLD $2.90 -0.1300 -4.29%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | Next > | Last >>

Cigna Agrees to Reduce H.I.V. Drug Costs for Some Florida Patients

(New York Times) Nov 7, 2014 - The health insurer Cigna has agreed to reduce the out-of-pocket costs that patients in Florida must pay for H.I.V. drugs, settling a complaint filed by advocacy groups, who said the drug pricing system in the state’s health care plans was discriminatory.
read article 



After Hepatitis C Cure, Companies Target Next Big Liver Disease Market

(Reuters) Nov 9, 2014 - Now that new medicines promise to cure millions of hepatitis C patients in coming years, drugmakers including Gilead Sciences Inc are turning their attention to other liver diseases, with a potential market that could rival the success of statins, which generated more than $30 billion a year in sales at their peak.
read article 



Merck's Four-Week Hepatitis C Regimen Fails to Top Gilead

(Bloomberg) Nov 10, 2014 - Merck & Co. won’t move forward with an ultra-short hepatitis C regimen that attempted to cut treatment durations in half by combining two of its drugs with another from Gilead Sciences Inc.
read article 



U.S. OKs Genetically Modified Potato with Lower Cancer Risk

(Reuters) Nov 7, 2014 - The U.S. Department of Agriculture on Friday approved the first genetically modified potato for commercial planting in the United States, a move likely to draw the ire of groups opposed to artificial manipulation of foods.
read article 



Dr. Candace Johnson Named Cancer Center Director at Roswell Park Cancer Institute

(RPCI) Nov 6, 2014 - Candace S. Johnson, PhD, has been promoted to Cancer Center Director at Roswell Park Cancer Institute, the only National Cancer Institute-designated comprehensive cancer center in Upstate New York.
read press release 



Roswell Park Acquires Breast Care of Western New York and Soniwala Hematology Oncology Associates

(RPCI) Nov 7, 2014 - Roswell Park Cancer Institute (RPCI) has acquired two established Western New York physician practices, increasing convenience and choice for cancer patients and unifying cancer surgical, medical and radiation services under the umbrella of the region’s only National Cancer Institute-designated Comprehensive Cancer Center.
read press release 



Meeting Encourages More Comprehensive End-of-life Care

(Reuters Health) Nov 10, 2014 - Physicians turned to contemplative techniques last week in New York to learn how to improve end-of-life care and handle the stress, burnout and communication challenges faced in caring for seriously ill patients.
read article 



USP Chapter 800 Proposal Delayed

(ASCO in Action) Nov 5, 2014 - The U.S. Pharmacopeia Convention (USP) recently announced it will publish a revised version of proposed General Chapter 800, “Hazardous Drugs – Handling in Healthcare Settings,” in early Spring 2015, following significant feedback received after the proposal’s release for public comment.
read article 



EDAP Receives FDA Guidance on PMA for Ablatherm-HIFU

(CNNMoney) Nov 6, 2014 - EDAP TMS SA, the global leader in therapeutic ultrasound, today received a letter from the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) on its current PMA application for Ablatherm Integrated Imaging Device.
read article 



Retesting Breast Cancer Axioms

(New York Times/Well blog) Nov 10, 2014 - The decisions American women make are often more strongly influenced by fear or a friend’s experience than by a thorough understanding of the benefits and risks of mammography.
read article 



American Cancer Society Includes Exact Sciences’ Cologuard in Colorectal Cancer Prevention and Early Detection Guidelines

(Yahoo! Finance) Nov 6, 2014 - Updated guidelines include recommended use of noninvasive stool-based DNA screening test every three years.
read article 



What Early Looks From ASH Tell Us About Cancer Immunotherapy

(Xconomy) Nov 7, 2014 - More cancer immunotherapy news will certainly emerge from the massive volume of abstracts between now and December 6, the first day of ASH. For now, there are several interesting developments to note.
read article 



Practice Makes Perfect in Cancer Surgery

(Queen's Gazette/Queen's University [Ontario, Canada]) Nov 7, 2014 - Queen's researchers determine higher hospital and surgeon volume lead to better outcomes when treating bladder cancer patients.
read article 



Researchers Take New Approach to Stop 'Most Wanted' Cancer Protein

(Dana-Farber) Nov 7, 2014 - Researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center have found a way to defeat one of the most tantalizing yet elusive target proteins in cancer cells – employing a strategy that turns the protein’s own molecular machinations against it.
read press release 



Mayo Clinic Researchers Identify First Steps in Formation of Pancreatic Cancer

(Mayo Clinic) Nov 10, 2014 - Researchers at Mayo Clinic’s campus in Jacksonville say they have identified first steps in the origin of pancreatic cancer and that their findings suggest preventive strategies to explore.
read press release 



Physicians Play a Critical Role in Ensuring Bladder Cancer Patients Understand the Link Between Smoking and Their Disease

(Wiley) Nov 10, 2014 - A new study published early online in CANCER reports that when bladder cancer patients are well-informed by their physicians, they acknowledge that tobacco use was likely the cause of their disease.
read corporate press release 



Dental Trauma May Play a Role in Oral Cancers

(Medscape Medical News) Nov 7, 2014 - Chronic dental irritation might play a role in the development of oral cancers, especially in nonsmokers, according to a study published online November 6 in JAMA Otolaryngology–Head & Neck Surgery.
read article (free registration required) 



Video-Assisted Thoracoscopic Surgery Technique for Pneumonectomy Shown to Be Safe

(RPCI) Nov 6, 2014 - In the largest series of its kind to date, researchers at Roswell Park Cancer Institute (RPCI) have shown that performing thoracoscopic pneumonectomy, removal of the entire lung through a minimally invasive endoscopic approach, at a high-volume center appears to be safe and may provide pain and survival advantages in the long term.
read press release 



Cigars Just as Harmful to Health as Cigarettes, Study Says

(FoxNews.com) Nov 10, 2014 - Cigar smokers are thought to inhale less smoke than cigarette smokers, leading some people to believe they pose fewer health risks than cigarettes. But new research published in the Nov. 7 issue of the journal Cancer, Epidemiology, Biomarkers & Prevention suggests that isn’t so.
read article 



OXiGENE Announces Presentation of Phase 2 Data Confirming That Addition of Fosbretabulin to Bevacizumab Significantly Increases Progression-Free Survival in Recurrent Ovarian Cancer

(CNBC) Nov 10, 2014 - OXiGENE, Inc. today announced the first presentation at a scientific conference of the positive results from the Phase 2 GOG 186I study of fosbretabulin combined with bevacizumab in recurrent ovarian, tubal and peritoneal carcinoma.
read article 



ArQule Announces Positive Top-Line Results of NIH-Sponsored Phase 2 Trial of Tivantinib in Prostate Cancer

(Yahoo! Finance) Nov 10, 2014 - Study met primary endpoint, significantly improving progression-free survival in tivantinib single agent arm compared to placebo arm.
read article 



The Next Chapter in Dendron's Troubled History: Chapter 11 Bankruptcy

(TheStreet) Nov 11, 2014 - A new chapter has been written in the Dendreon story. Unfortunately, it's Chapter 11.
read article 



Medicare Costs For Breast Cancer Screenings Soar, But Benefits Remain Unclear

(New Haven Register [CT]) Nov 9, 2014 - The cost of Medicare-funded breast cancer screenings jumped 44 percent from $666 million to $962 million from 2001 to 2009, yet those added millions did not improve early detection rates among the 65 and older Medicare population, according to a Yale study.
read article 



Boehringer Reports Data from Afatinib Phase III LUX-Lung 3 Trial in Asian NSCLC Patients

(Pharmaceutical Business Review) Nov 10, 2014 - Boehringer Ingelheim has reported positive data from a pre-specified subgroup-analysis of the pivotal Phase III LUX-Lung 3 trial of afatinib in Asian non-small cell lung cancer (NSCLC) patients.
read article (free registration required) 



New Subgroup Analysis Shows Asian Non-small Cell Lung Cancer Patients with Most Common EGFR Mutation (del19) Lived Significantly Longer with First-line GIOTRIF® (afatinib*) Compared to Chemotherapy

(Boehringer Ingelheim) Nov 7, 2014 - Boehringer Ingelheim today announced data from a pre-specified subgroup-analysis of the pivotal Phase III LUX-Lung 3 trial which demonstrated that Asian non-small cell lung cancer (NSCLC) patients with the most common type of EGFR mutation, (exon 19 deletion; del19), lived significantly longer after receiving first-line treatment with afatinib compared to chemotherapy (33.3 vs 22.9 months, respectively).
read corporate press release